Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004037 | 0.82 | DCTPP1 (0.33) | CYP1A2TSHRDCTPP1BRD4NPC1 | |
| SCHEMBL3673095 | 0.80 | DCTPP1 (0.35) | CYP1A2TSHRDCTPP1BRD4NPC1 | |
| SCHEMBL23291824 | 0.77 | TP53 (0.37) | CYP1A2TSHRMAPTLMNATP53 | |
| SCHEMBL15476255 | 0.77 | TP53 (0.37) | CYP1A2TSHRMAPTLMNATP53 | |
| SCHEMBL13122596 | 0.76 | KDM4E (0.58) | MAPTLMNADCTPP1BRD4NPC1 | |
| SCHEMBL19023458 | 0.76 | BRD4 (0.44) | MAPTBRD4NPC1TDP1 | |
| SCHEMBL29835911 | 0.76 | GALR3 (0.40) | TSHRMAPTLMNATP53BRD4 | |
| SCHEMBL13122602 | 0.76 | TDP1 (0.41) | TSHRMAPTLMNATP53BRD4 | |
| SCHEMBL29985422 | 0.76 | KDM4E (0.45) | MAPTLMNATP53DCTPP1BRD4 | |
| SCHEMBL2144844 | 0.76 | GALR3 (0.40) | TSHRMAPTLMNATP53BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070888-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | OPRD1, OPRK1, OPRL1 | CYP1A2 24/4885TSHR 924/4885MAPT 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.